Opendata, web and dolomites

PRISM SIGNED

Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "PRISM" data sheet

The following table provides information about the project.

Coordinator
RIJKSUNIVERSITEIT GRONINGEN 

Organization address
address: Broerstraat 5
city: GRONINGEN
postcode: 9712CP
website: www.rug.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 17˙099˙552 €
 EC max contribution 8˙080˙000 € (47%)
 Programme 1. H2020-EU.3.1.7.4. (Diabetes)
 Code Call H2020-JTI-IMI2-2015-03-two-stage
 Funding Scheme /IMI2-RIA
 Starting year 2016
 Duration (year-month-day) from 2016-04-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) coordinator 2˙104˙981.00
2    P1VITAL LIMITED UK (WALLINGFORD) participant 1˙226˙586.00
3    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 840˙000.00
4    STICHTING VUMC NL (AMSTERDAM) participant 775˙000.00
5    CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES (MADRID) participant 648˙000.00
6    SBGNeuro Limited UK (THAME) participant 490˙000.00
7    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 350˙000.00
8    BIOTRIAL SAS FR (RENNES) participant 350˙000.00
9    Concentris Research Management GmbH DE (Fürstenfeldbruck) participant 315˙000.00
10    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) participant 301˙870.00
11    DRUG TARGET ID BV NL (NIJMEGEN) participant 200˙000.00
12    STICHTING BURO ECNP NL (UTRECHT) participant 170˙000.00
13    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 100˙000.00
14    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 100˙000.00
15    THE UNIVERSITY OF EXETER UK (EXETER) participant 90˙000.00
16    European Federation of Associations of Families of People with Mental Illness BE (LEUVEN) participant 18˙563.00
17    Boehriger Ingelheim International GmbH DE (INGELHEIM) participant 0.00
18    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
19    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
20    Janssen Pharmaceutica NV BE (BEERSE) participant 0.00
21    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
22    PFIZER LIMITED UK (SANDWICH) participant 0.00
23    Takeda Development Centre Europe Ltd. UK (LONDON) participant 0.00

Mappa

 Project objective

The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has dramatically stagnated in the past decades. In a coordinated effort encompassing academic experts, SMEs, patient and family organizations, regulators, ECNP and EFPIA partners, this project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients. This project will concentrate on Schizophrenia (SZ), Alzheimer’s disease (AD), and Major Depression (MD), as these disorders share part of their symptomatology, in particular social withdrawal and certain cognitive deficits, such as deficits in attention, working memory and sensory processing. By applying innovative technologies (e.g. EEG, cognitive tasks, (f)MRI, smartphone monitoring, and (epi-)genetics) to deep phenotype a clinical cohort of SZ and AD patients combined with a wider analysis of existing clinical data sets from major European and global disease cohorts that also include MD, we will define a set of quantifiable biological parameters best able to cluster and differentiate SZ, AD, and MD patients that do, or do not, exhibit social withdrawal. First, by mining large European SZ, AD and MD cohort datasets with already available social and cognitive proxy measures, and, second, by obtaining objective measures of social exploration levels (using a novel smartphone application), phenotypic relationships with social and cognitive measures will be further tested. For instance we might predict that socially withdrawn individuals may have lower cognitive functioning and poorer clinical course compared to those who are more socially engaged. The two approaches will then come together via selected individuals with low or high social withdrawal who have also been assessed in the deep phenotyping study using integrated behavioural, cognitive, attentional, sensory processing, EEG, and MRI data. In phase I of the project (years 1-3), the clinical deep phenotyping study will provide a proof-of-concept analysis for this quantitative biological approach and will concentrate on SZ and AD patients. To identify shared genetic factors potentially related to the social withdrawal symptom and cognitive deficits observed in these disorders, a cross-disorder genome-wide genetic analysis will be performed in the largest world-wide available samples of SZ, AD, and MD patients. Genetic associations from the global cohorts will be evaluated for their relevance for social withdrawal and cognitive deficits in subsamples with relevant (proxy) phenotypes in large and available European cohorts that have genetic data and clinical proxy data on social withdrawal, sensory processing, attention and working memory available. Data integration of genetic and epigenetic studies through an innovative molecular landscaping approach will lead to the identification of new biological substrates and candidate genes underlying these phenotypic domains. These will provide the basis for reverse translation and construct validation studies in rodents which will be tested in behavioural, cognitive, EEG and O2 amperometry paradigms that are homologous to those performed in the clinical deep phenotyping study. Where appropriate, the clinical studies will inform on the use of appropriate perturbations, including genetic modification to the systems and substrates being probed. Additional preclinical studies will extend the characterisation of the substrates underlying the integrated socio-cognitive traits beyond simple reverse translation by exploiting higher spatial or temporal resolution techniques such as 2-photon imaging, single unit electrophysiology, in vivo micro-dialysis and biosensors. Together, these studies will provide new classification and assessment tools

 Work performed, outcomes and results:  advancements report(s) 

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PRISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PRISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.4.)

PRISM (2016)

Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD

Read More  

INNODIA (2015)

Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes.

Read More